Alzamend Neuro, Inc. - 8-K Filing

Alzamend Neuro pauses Bipolar Disorder clinical trial following negative FDA feedback and terminates Statement of Work with Massachusetts General Hospital.

3 articles from 1 source · updated

Coverage